Page 98 - 01.pdf

NOTICE OF ANNUAL GENERAL MEETING
ASIAMEDIC LIMITED
ANNUAL REPORT 2013 96
Notes:
1. A member of the Company entitled to attend and vote at the Meeting is entitled to appoint a proxy and vote on
his stead.
2. Such proxy need not be a member of the Company.
3. If the appointer is a corporation, the proxy must be executed under seal or the hand of its duly authorised officer
or attorney.
4. The instrument appointing a proxy must be deposited at the registered office of the Company at 350 Orchard
Road, #08-00 Shaw House, Singapore 238868 not later than 48 hours before the time appointed for the Meeting.
Explanatory Notes:
1. Resolution 6, if passed, will empower the Directors of the Company from the date of the above Meeting until
the next annual general meeting to issue Shares and convertible securities in the Company up to an amount not
exceeding in aggregate 100% of the total number of issued Shares excluding treasury shares of the Company,
of which the total number of Shares and convertible securities issued other than on a pro rata basis to existing
shareholders shall not exceed 50% of the total number of issued Shares excluding treasury shares of the
Company at the time the Resolution is passed, for such purposes as they consider would be in the interests of
the Company. The Rules of Catalist currently provide that the total number of issued Shares excluding treasury
shares of the Company for this purpose shall be the total number of issued Shares excluding treasury shares
at the time this Resolution is passed (after adjusting for new Shares arising from the conversion of convertible
securities or share options on issue at the time this Resolution is passed and any subsequent bonus issue,
consolidation or subdivision of the Company’s Shares). This authority will, unless revoked or varied at a general
meeting, expire at the next annual general meeting of the Company.
2. Resolution 7, if passed, will empower the Directors, from the date of the above meeting until the next annual
general meeting, to repurchase Shares by way of market purchases or off-market purchases of up to ten
per cent. (10%) of the issued ordinary share capital of the Company at such price up to the Maximum Price.
Information relating to this proposed Resolution is set out in the Appendix attached to the Annual Report.
3. Resolution 8, if passed, will empower the Directors to offer and grant awards in accordance with the AsiaMedic
Share Award Scheme and to issue shares in the capital of the Company pursuant to the granting of Awards
under the Scheme.
This notice has been prepared by the Company and reviewed by the Company’s sponsor, Asiasons WFG Capital Pte
Ltd (the “Sponsor”), for compliance with the Listing Manual (Section B: Rules of Catalist) of the Singapore Exchange
Securities Trading Limited (the “SGX-ST”). The Sponsor has not independently verified the contents of this notice
including the accuracy or completeness of any of the information disclosed or the correctness of any of the statements
made, opinions expressed or reports contained in this notice. This notice has not been examined or approved by the
SGX-ST. The SGX-ST and the Sponsor assume no responsibility for the contents of this notice including the correctness
of any of the statements made, opinions expressed or reports contained in this notice.
Contact person for the Sponsor: Ms Pauline Sim (Registered Professional, Asiasons WFG Capital Pte Ltd)
Address: 22 Cross Street, #03-54/61 China Square Central, Singapore 048421
Telephone number: (65) 6319 4954